演題詳細

一般口演 / Oral Session

一般口演 86 (Oral Session 86) :骨髄腫:再発難治・治療

print

日程
2013年10月13日(日)
時間
08:45 - 09:45
会場
第10会場 / Room No.10 (ロイトン札幌 20F パールホールAB)
座長・司会
伊藤 薫樹 (Shigeki Ito):1
1:岩手医科大学 血液・腫瘍内科
 
前へ戻る

Lenalidomide and dexamethasone for relapsed/refractory multiple myeloma in Kansai Myeloma Forum

演題番号 : OS-3-73

古林 勉 (Tsutomu Kobayashi):1、黒田 純也 (Junya Kuroda):1、太田 健介 (Kensuke Ohta):2、田中 宏和 (Hirokazu Tanaka):3、柴山 浩彦 (Hirohiko Shibayama):4、小原 尚恵 (Takae Kohara):4、小杉 智 (Satoru Kosugi):5、木田 亨 (Toru Kida):5、淵田 真一 (Shin-Ichi Fuchida):6、宮本 和恵 (Kazue Miyamoto):7、新堂 真紀 (Maki Shindo):7、小林 正行 (Masayuki Kobayashi):7、金子 仁臣 (Hitomi Kaneko):8、魚嶋 伸彦 (Nobuhiko Uoshima):9、松村 弥生 (Yayoi Matsumura):9、吉井 由美 (Yumi Yoshii):9、上辻 由里 (Yuri Kamitsuji):9、石井 一慶 (Kazuyoshi Ishii):10、松田 光弘 (Mitsuhiro Matsuda):10、高橋 隆幸 (Takayuki Takahashi):10、濱田 常義 (Tsuneyoshi Hamada):10、通堂 満 (Mitsuru Tsudo):8、島崎 千尋 (Chihiro Shimazaki):6、高折 晃史 (Akifumi Takaori):7、野村 昌作 (Shosaku Nomura):10、日野 雅之 (Masayuki Hino):10、松村 到 (Itaru Matsumura):3、谷脇 雅史 (Masafumi Taniwaki):1、金倉 譲 (Yuzuru Kanakura):4

1:Div. Hematol. and Oncol., Kyoto Pref. Univ. of Med., Japan、2:Dept. of Hematol., Osaka Saiseikai Nakatsu Hospital, Japan、3:Dept. of Hematol. and Rheumatol., Kinki University Faculty of Medcine, Japan、4:Dept. Hematol. Oncol., Osaka University Graduate School of Medicine, Japan、5:Dept. of Int. Med., Toyonaka Municipal Hospital, Japan、6:Dept. of Hematol., Social Insurance Kyoto Hospital, Japan、7:Dept. Hematol. Oncol. Graduate School of Medicine, Kyoto University, Japan、8:Dept. of Hematol., Osaka Red Cross Hospital, Japan、9:Dept. of Hematol., Matsushita Memorial Hospital, Japan、10:Kansai Myeloma Forum

 

Introduction: We have founded Kansai Myeloma Forum (KMF) for the purpose of registering the patients with myeloma-related disease in Kansai area. We retrospectively analyzed the outcome of refractory/relapsed (RRMM) in KMF those are treated by Lenalidomide plus weekly dexamethasone (Rd). Patients and Methods: Among 923 patients (Pts) registered in KMF, we analyzed 100 RRMM Pts treated by Rd from Jan, 2006 to Mar, 2013. Results: The median age was 67 (36-82). Of the 83 patients evaluable for staging, 21 were classified as stage I, 39 as stage II, and 23 as stage III according to ISS. Overall response rate was 64.6%, including 34.1% of better than VGPR. At 8.7 months follow-up, median OS and time to next treatment (TTNT) was 23.6 and 16.0 months, respectively. Less than 2 regimens prior to Rd and shorter duration from the initial diagnosis to the initiation of Rd (less than 24 months) significantly associated with longer OS (P=0.016 and not reached vs. 17.9 months, P=0.003, respectively) and also tended to associate with longer TTNT (24.0 vs. 14.0 months, and 31.0 vs. 13.0 month). Prior use of thalidomide significantly associated with the shorter OS (P=0.011) and tended to associate with the shorter TTNT. Importantly, ISS, age, prior bortezomib and prior high dose therapy with stem cell transplantation had no impact on the long-term outcome in our cohort. Conclusion: Our results suggest that earlier use of Rd as the salvage therapy associates with more favorable survival benefit for RRMM.

前へ戻る